Showing 1 - 5 results of 5 for search 'Alberto Cruz-Bermúdez', query time: 4.06s Refine Results
  1. 1
    The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy

    The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy by Alberto Cruz-Bermúdez, Raquel Laza-Briviesca, Marta Casarrubios, Belén Sierra-Rodero, Mariano Provencio

    Published 2021-03-01
    Get full text
    Article
  2. 2
    Functional Characterization of Three Concomitant MtDNA LHON Mutations Shows No Synergistic Effect on Mitochondrial Activity.

    Functional Characterization of Three Concomitant MtDNA LHON Mutations Shows No Synergistic Effect on Mitochondrial Activity. by Alberto Cruz-Bermúdez, Ramiro J Vicente-Blanco, Rosana Hernández-Sierra, Mayte Montero, Javier Alvarez, Mar González Manrique, Alberto Blázquez, Miguel Angel Martín, Carmen Ayuso, Rafael Garesse, Miguel A Fernández-Moreno

    Published 2016-01-01
    Get full text
    Article
  3. 3
    Molecular Divergence upon <i>EGFR</i>-TKI Resistance Could Be Dependent on the Exon Location of the Original <i>EGFR</i>-Sensitizing Mutation

    Molecular Divergence upon <i>EGFR</i>-TKI Resistance Could Be Dependent on the Exon Location of the Original <i>EGFR</i>-Sensitizing Mutation by Roberto Serna-Blasco, Estela Sánchez-Herrero, Lucía Robado de Lope, Sandra Sanz-Moreno, Alejandro Rodríguez-Festa, Dunixe Ares-Trotta, Alberto Cruz-Bermúdez, Fabio Franco, Alfredo Sánchez-Hernández, María de Julián Campayo, Carlos García-Girón, Manuel Dómine, Ana Blasco, José M. Sánchez, Juana Oramas, Joaquim Bosch-Barrera, María Á. Sala, María Sereno, Atocha Romero, Mariano Provencio

    Published 2022-09-01
    Get full text
    Article
  4. 4
    Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial by Amelia Insa, Mariano Provencio, Bartomeu Massutí, Margarita Majem, Delvys Rodriguez-Abreu, Manuel Cobo, Manuel Dómine, Joaquín Casal-Rubio, Ernest Nadal, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Yago Garitaonaindía, Joaquín Mosquera, Alex Martinez-Marti, Javier De Castro Carpeño, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Raquel Laza-Briviesca, Marta Casarrubios, Aránzazu García-Grande, Atocha Romero, Fernando Franco

    Published 2021-08-01
    Get full text
    Article
  5. 5
    Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

    Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial by Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, María del Rosario García‐Campelo, Gerardo Huidobro, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Marta Casarrubios, Belén Sierra‐Rodero, Carlos Tarín, Aránzazu García‐Grande, Cara Haymaker, Ignacio I. Wistuba, Atocha Romero, Fernando Franco, Mariano Provencio

    Published 2021-07-01
    Get full text
    Article

Search Tools: